2021 CCM Scientific Conference w/ Andrea Taddei

Our Director of Drug Discovery, Andrea Taddei, will discuss how we’re using AI to unravel CCM biology and identify potential therapeutic targets. 

Cerebral Cavernous Malformation (CCM) is a disease of the central nervous system (CNS) that is characterised by the formation of clusters of capillary lesions, primarily within the CNS. Clinical manifestations range from headaches to seizures, intracranial haemorrhages (ICH), and focal neurological deficits. No pharmacological treatment is currently available, and the only intervention option is neurosurgery, which is often not possible due to the low accessibility of the CCM lesions.

In collaboration with UC San Diego, we are leveraging our Knowledge Graph and AI-driven Target Identification capabilities to identify new therapeutic targets for CCM. The Target Identification process involves enhancing the Benevolent Knowledge Graph with public and proprietary transcriptomics datasets. Predictive target identification algorithms were used to suggest a list of targets, with a focus on processes that drive disease pathophysiology. The target list was triaged by expert vascular biologists, with BenevolentAI’s tools providing the accompanying metadata from the Knowledge Graph, including information on the ligandability, novelty, safety, and expression pattern of the targets suggested by the AI models. 

With very few drugs reaching the clinical development stage for CCM, this disease remains an area of high unmet patient need. Our collaboration with UC San Diego is focused on exploring pathways that have not previously been investigated for the treatment of CCM, with the aim of providing a much-needed non-surgical option for CCM patients. 

Register here →

More Posts

You Might Also Like

Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022